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Histone deacetylation and DNA methylation have a central role in the control of gene expression in tumours, including
transcriptional repression of tumour suppressor genes and genes involved in sensitivity to chemotherapy. Treatment of cisplatin-
resistant cell lines with an inhibitor of DNA methyltransferases, 2-deoxy-50azacytidine (decitabine), results in partial reversal of DNA
methylation, re-expression of epigenetically silenced genes including hMLH1 and sensitisation to cisplatin both in vitro and in vivo.W e
have investigated whether the combination of decitabine and a clinically relevant inhibitor of histone deacetylase activity (belinostat,
PXD101) can further increase the re-expression of genes epigenetically silenced by DNA methylation and enhance chemo-
sensitisation in vivo at well-tolerated doses. The cisplatin-resistant human ovarian cell line A2780/cp70 has the hMLH1 gene
methylated and is resistant to cisplatin both in vitro and when grown as a xenograft in mice. Treatment of A2780/cp70 with decitabine
and belinostat results in a marked increase in expression of epigenetically silenced MLH1 and MAGE-A1 both in vitro and in vivo when
compared with decitabine alone. The combination greatly enhanced the effects of decitabine alone on the cisplatin sensitivity of
xenografts. As the dose of decitabine that can be given to patients and hence the maximum pharmacodynamic effect as a
demethylating agent is limited by toxicity and eventual re-methylation of genes, we suggest that the combination of decitabine and
belinostat could have a role in the efficacy of chemotherapy in tumours that have acquired drug resistance due to DNA methylation
and gene silencing.
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Epigenetic inactivation of genes crucial for control of normal cell
growth is a hallmark of cancer cells (Hanahan and Weinberg,
2000). These epigenetic mechanisms include crosstalk between
DNA methylation, histone modification and other components of
chromatin higher order structure leading to regulation of gene
transcription. The transfer of a methyl group to the carbon 5
position of cytosines, almost always in the context of CpG
dinucleotides, is the only known epigenetic modification of DNA
itself in mammalian cells. Many tumours show increased
methylation of CpG islands, CpG rich regions of DNA usually
although not exclusively associated with gene promoters, which is
associated with epigenetic silencing (Brown and Strathdee, 2002).
CpG islands aberrantly methylated in tumours are associated with
silencing of genes involved in control of the cell cycle, apoptosis
and drug sensitivity as well as tumour suppressor genes (Brown
and Plumb, 2004).
Epigenetic silencing occurring during tumour development has
the potential to affect the chemo-sensitivity of tumour cells and
how tumours will respond to chemotherapy (Teodoridis et al,
2005). One example of this is epigenetic inactivation of the CpG
island at the DNA repair gene, MGMT and response of glioma to
monofunctional alkylating agents such as temozolomide (Hegi
et al, 2005). DNA methylation and epigenetic silencing of tumour
cells can also be selected for during chemotherapy and may be
an important driving force behind acquired drug resistance
(Glasspool et al, 2006). The MLH1 protein, part of the human
DNA mismatch repair system, has been shown to be important in
determining sensitivity to a number of important chemo-
therapeutic agents including alkylating agents and cisplatin (Fink
et al, 1998; Brown, 1999). Loss of mismatch repair due to
methylation of the hMLH1 gene promoter results in resistance to
cisplatin in cell lines in vitro and in human tumour xenografts in
vivo (Plumb et al, 2000). Methylation of the hMLH1 gene promoter
is observed in many tumour types (Strathdee et al, 1999; Gifford
et al, 2004) and loss of MLH1 expression is associated with clinical
drug resistance in ovarian cancer (Samimi et al, 2000).
There is considerable interest in the potential to use epigenetic
therapies in combination with existing chemotherapeutic agents,
both for improving initial tumour response and for overcoming
acquired drug resistance. We have previously shown that
treatment of ovarian and colon cell lines with the DNA
hypomethylating agent 2-deoxy-50azacytidine (decitabine, DAC)
results in partial reversal of DNA methylation, re-expression of
methylated loci such as hMLH1 and sensitisation to cisplatin and
carboplatin both in vitro and in vivo (Plumb et al, 2000). In studies
of human tumour xenografts in mice we were able to demonstrate
that decitabine treatment reduced the level of methylation of the
hMLH1 gene promoter and that this was associated with re-
expression of MLH1 in a small proportion of the tumour cells at
doses that clearly conferred increased sensitisation and were well
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stolerated. In a phase 1 clinical trial of decitabine in combination
with carboplatin in advanced solid tumours, a reduction in
methylcytosine content of PBMCs was observed that was compar-
able to that observed in mice where chemo-sensitisation of
xenografts occurred (Appleton et al, 2007). However, limited
demethylation of tumour was observed. The dose limiting toxicity
of decitabine was identified as myelosuppression and this toxicity
plus the limited demethylation in tumours and eventual re-
methylation of genes may limit the clinical use of decitabine when
used alone in solid tumours.
Baylin and co-workers have shown that the combination of
the histone deacetylase (HDAC) inhibitor trichostatin A with
decitabine is more effective in reactivating transcription of
epigenetically silenced genes such as hMLH1 in tumour cell lines
than either drug alone (Cameron et al, 1999). The combination
of a demethylating agent and an HDAC inhibitor has now been
examined in clinical trials of haematological malignancies.
However, in solid tumours it may be that epigenetic therapies
may be more effective when used in combination with cyto-
toxic agents. We have therefore investigated whether it is
possible to use a low, non-toxic dose of decitabine in combination
with an inhibitor of histone deacetylase activity, belinostat
(PXD101), to enhance the level of re-expression of epigenetically
silenced genes in drug-resistant A2780/cp70 both in vitro and
in vivo and whether this combination enhances chemo-sensitisa-
tion of xenografts.
MATERIALS AND METHODS
Cell lines
Cell line A2780/cp70 is an in vitro derived cisplatin-resistant
variant of the ovarian cancer cell line A2780 originally obtained
from Dr RF Ozols (Fox Chase Cancer Centre, Philadelphia, PA,
USA). Cells were grown in RPMI-1640 supplemented with
glutamine (2mM) and FCS (10%). A2780/cp70 is mismatch repair
deficient and does not express MLH1 due to hypermethylation of
the hMLH1 gene promoter (Strathdee et al, 1999) as well as having
a number of other loci hypermethylated (Leu et al, 2003).
Protein expression
For western blotting cells were grown in 25cm
2 flasks and exposed
to drugs as specified. Cells were harvested with trypsin/EDTA and
washed two times with ice cold PBS. They were resuspended in
200ml of lysis buffer (50mM Hepes pH 7.0, 250mM NaCl, 0.5%
NP40) supplemented with protease inhibitors (Complete from
Roche Diagnostics Ltd, Lewes, UK) and incubated on ice for
20min. Samples were centrifuged at 12000g for 5min at 41Ct o
remove debris. Supernatant proteins (20mg) were separated by the
NuPage electrophoresis system (Invitrogen, Paisley, UK) on 4–
12% Bis-Tris gels with 4-morpholinepropanesulfonic acid SDS
running buffer. The ‘Novex Xcell II’ blotting apparatus (Invitrogen)
was used to transfer proteins onto Immobilon polyvinylidene
difluoride membrane (Millipore, Watford, UK). The membrane
was blocked for 1h in Tris-buffered saline containing 0.02% Tween
20 and 5% powdered milk and then incubated overnight at 41C
with the primary antibody (MLH1 from Pharmingen, BD UK Ltd,
Oxford, UK, MAGE-A1 from Neomarkers, Lab Vision Ltd,
Cambridge, UK). The membrane was then washed and incubated
for 1h at room temperature with the secondary antibody (sheep
anti-mouse HRP, Amersham, GE Healthcare, Amersham, UK). After
washing, the membrane protein bands were visualised by enhanced
chemiluminescence (ECL, Amersham). Band intensity was quanti-
fied by densitometry (GS-800, Bio-Rad, Hemel Hempstead, UK).
For immunohistochemistry, tumours were fixed in neutral-
buffered formalin and processed as previously described (Plumb
et al, 2000).
Human tumour xenografts
Animal studies were carried out under an appropriate United
Kingdom Home Office Project Licence and all work conformed to
the UKCCR Guidelines for the welfare of animals in experimental
neoplasia. Monolayer cultures were harvested with trypsin/EDTA
and resuspended in PBS. About 10
7 cells were injected sub-
cutaneously into the right flank of athymic nude mice (CD1 nu/nu
mice from Charles River, Margate, UK). After 7–10 days when the
mean tumour diameter was at X0.5cm, animals were randomised
in groups of six for experiments. Standard sterile clinical
formulations of cisplatin (Western Infirmary Pharmacy, Glasgow)
decitabine (Supergen, Dublin, California, CA, UK) and belinostat
(TopoTarget, Abingdon, UK) were used. Where specified, mice
were pretreated with decitabine 6 days before cisplatin (6mgkg
 1
intraperitoneally), when tumours were just visible. Decitabine
(5mgkg
 1) was administered intraperitoneally at 10:00, 13:00 and
16:00 hours (total dose 15mgkg
 1 per mouse). Belinostat
(40mgkg
 1) was administered intraperitoneally 3 days before
cisplatin where specified. Mice were weighed daily and tumour
volumes were estimated by caliper measurements assuming
spherical geometry (volume¼d
3 p/6).
Pyrosequencing
The methylation status of specific cytosine residues in the MAGE-
A1 gene promoter was determined following bisulphite modifica-
tion of DNA extracted from tumours. Tumours were removed
from mice and snap frozen in liquid nitrogen. Frozen tumours
were powdered in a ‘Mikro-Dismembrator’ homogeniser and
DNA extracted with a BACC2 Nucleon extraction kit (Nucleon).
Bisulphite modification was carried out with the CpGenome DNA
modification kit (Chemicon International, Millipore, Watford, UK)
according to the manufacturer’s instructions. The modified
DNA was amplified by PCR with primers chosen to bracket
the CpG island of the MAGE-A1 gene promoter (forward PCR:
50-TTTTTATTTTTATTTAGGTAGGAT-30 and reverse PCR: Biotin-
50-TCTAAAAACAACCCAAACTAAAAC-30). The PCR was carried
out in 50ml volumes containing 2U Faststart Taq polymerase,
10  Faststart Buffer (Roche), 10mM dNTPs (Applied Biosystems,
Warrington, UK), 3.5mM MgCl2 (Roche), oligonucleotides
(Biomers, www.biomers.net) at 1mM and 2ml of modified DNA
template. A 40-ml PCR product was used for pyrosequencing
according to the manufacturer’s instruction. Sixteen picomoles of
the sequencing primers (50-TGTTGTTAGTTTTGGTTTAT-30) were
applied to detect the presence or absence of methylation.
RESULTS
Re-expression of MLH1 and MAGE-A1 in vitro by
decitabine and belinostat
Treatment of MLH1 negative A2780/cp70 cells on days 1 and 2 with
decitabine results in a dose-dependent re-expression of MLH1 as
measured by western blot 3, 6 and 9 days after the start of
treatment (Figure 1A). Belinostat treatment alone had no
detectable effect on MLH1 levels. Treatment with decitabine on
day 1 and with both decitabine and belinostat on day 2 results in a
marked increase in MLH1 expression compared to treatment with
decitabine alone on days 1 and 2. Re-expression of MLH1 was
transient following treatment with decitabine at 0.1mM (Figure 1B)
but was more sustained at 0.2mM (Figure 1C). Addition of
belinostat increased the level of expression of MLH1 but did not
alter the time course of re-expression or re-silencing. Decitabine
treatment also induced re-expression of MAGE-A1 and again
the expression was enhanced by the addition of belinostat.
Re-expression of MAGE-A1 was transient at both concentrations
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sof decitabine and belinostat and did not alter the time course of
MAGE-A1 re-expression or re-silencing (Figure 1B and C).
Re-expression of MLH1 and MAGE-A1 in vivo by
decitabine and belinostat
Treatment of mice with decitabine induces re-expression of MLH1
in A2780/cp70 xenografts and expression is maximal by about day
9 (Figure 2A and B). A similar time course is observed for MAGE-
A1 expression (Figure 2C). Belinostat alone has no detectable effect
on MLH1 and MAGE-A1 expression. The combination of
decitabine and belinostat produces a marked increase in the level
of re-expression of both MLH1 and MAGE-A1 to a greater extent
than that achieved with decitabine alone (Figure 2). Gene re-
expression is detectable by immunocytochemistry in only about
10% of cells and these cells appear in clusters following decitabine
and belinostat treatment (Figure 2A, day 12).
Methylation of MAGE-A1
Cytosine methylation was examined at 3 CpG sites within the MAGE-
A1 gene promoter. At each site the level of methylation was reduced by
decitabine treatment but there was no further reduction following
treatment with decitabine and belinostat in combination (Figure 3).
Although only between 6 and 20% demethylation is observed at these
sites it should be noted that this will be an average throughout the cell
population and only those cells, which are proliferating will incorporate
decitabine and become demethylated. Global 5-methyl-20-deoxy-
cytidine levels in DNA from the tumours taken on day 6 was measured
by HPLC (Appleton et al, 2007). Decitabine treatment reduced cytosine
methylation (5-methyl-20-deoxycytidine as a percentage of total 20-deoxy-
cytidine) from 3.43±0.16 in the control tumours to 2.78±0.05 (n¼3,
Po0.01) and this was not significantly different from the levels observed
in the tumours taken from mice treated with decitabine in combination
with belinostat (2.92±0.12, n¼3) Belinostat treatment had no effect on
5-methyl-20-deoxycytidine levels (3.70±0.28, n¼3).
Effects of decitabine and belinostat pre-treatment on drug
sensitivity
A2780/cp70 is resistant to the maximum-tolerated dose of cisplatin
in vivo. Treatment with decitabine or belinostat either alone or in
combination has no effect on tumour growth and belinostat did
not sensitise tumours to cisplatin. Pre-treatment of the mice with
decitabine 6 days before treatment with cisplatin results in a
significant growth delay and this effect is enhanced by the
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Figure 1 (A) MLH1 expression determined by western blotting of A2780/cp70 cell lysates prepared at various times after treatment of cells with DAC
either alone or in combination with belinostat (PXD101). Cells were treated for 48h (days 1 and 2) with decitabine with belinostat added for the second
24h (day 2). MLH1 and MAGE-1a expression determined by western blotting and quantified by densitometry at various times after treatment of
A2780/cp70 cells with either decitabine (B) 0.1mM,( C) 0.2mM; filled bars) or decitabine and belinostat (0.1mM; hatched bars). Results shown are
representative of one of three experiments.
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scombination of decitabine and belinostat (Figure 4A). The
treatments were well tolerated by the mice and there was no
significant effect on body weight (Figure 4B).
DISCUSSION
We have shown clearly that the combination of low doses of
decitabine and belinostat results in re-expression of epigenetically
silenced genes and that when used in vivo in mice the combination
can sensitise drug-resistant tumours to cisplatin more effectively
than either drug alone.
We have already established that decitabine can be used to
sensitise drug-resistant tumours to a number of clinically relevant
cytotoxic drugs including cisplatin, carboplatin, epirubicin and
temozolomide (Plumb et al, 2000). The inclusion of pharmaco-
dynamic measurements in a phase 1 trial of decitabine and
carboplatin has enabled us to show that decitabine can induce in
patients the levels of demethylation in surrogate PBMCs seen in
our mouse studies at doses that cause chemo-sensitisation
(Appleton et al, 2007). However, it is also clear from the phase 1
trial that demethylation in PBMCs by decitabine is limited by the
myelosuppressive activity of the drug. The level of demethylation
observed in tumours was limited and heterogeneous between
patients. In order to potentially increase the reversal of epigenetic
silencing by decitabine, we have examined the addition of an
HDAC inhibitor on re-expression of epigenetically silenced genes
and chemo-sensitisation. Belinostat alone has no effect on MLH1
expression and this is consistent with the observation that histone
deacetylase inhibitors cannot induce the expression of genes
silenced due to promoter methylation (Suzuki et al, 2002). From
the results with the cell line it is clear that belinostat can enhance
the effects of decitabine on gene re-expression (Figure 1). Although
belinostat increases the level of re-expression of both MLH1 and
MAGE-A1 it does not appear to alter the kinetics of re-expression.
This is consistent with the observation that the HDAC inhibitor
4-phenylbutyric acid does not inhibit re-silencing of p16 after
decitabine treatment (Egger et al, 2007). Re-expression of MAGE-
A1 is transient. It can be detected by 3 days after treatment but is
lost after about 26 days. Re-expression of MLH1 is also transient at
lower concentrations of decitabine (0.1mM), but is more sustained
at the higher concentration (0.2mM) such that it remains detectable
after 26 days. This may reflect the long half-life of the protein or
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Figure 2 (A) MLH1 and MAGE-1A expression detected by immuno-
histochemistry in A2780/cp70 xenografts 12 days after treatment with
decitabine (5mgkg
 1 3 on day 0) alone or followed by belinostat
(40mgkg
 1 on day 3). (B) MLH1 and MAGE-1a expression at various
times after treatment with belinostat (open bars), decitabine (hatched bars)
or decitabine and belinostat (filled bars). (C) Expression is quantified as the
percentage of cells that stain positive (þve).
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Figure 3 Pyrosequencing analysis of methylation of three CpG sites
within a CpG island in the MAGE-1a gene promoter in A2780/cp70
xenografts. Mice were treated with decitabine alone on day 0
(5mgkg
 1 3; stippled bars), belinostat alone on day 3 (40mgkg
 1; filled
bars) or with the combination of decitabine on day 0 and belinostat on day
3 (hatched bars). Tumours were removed and cytosine methylation
measured on day 0 (untreated) and on days 6, 9 and 12. Cytosine
methylation at three CpG sites within the MAGE-A1 promoter (CpG 17
(A), CpG 18 (B) and CpG 19 (C)) was determined.
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smay be due to a slower rate of gene re-methylation at the higher
dose of decitabine.
To study the combination in human tumour xenografts we used
the same schedule for decitabine that was shown to sensitise the
tumours to cisplatin (Plumb et al, 2000) and attempted to improve on
this response. Initial studies investigated the effects on gene re-
e x p r e s s i o na n dw eh a v es h o w nt h a tas i n g l ed o s eo fb e l i n o s t a t
administered 3 days after decitabine treatment results in an increase
in expression of both MLH1 and MAGE-A1 to a level greater that is
seen with decitabine alone (Figure 2). MLH1 and MAGE-A1 gene re-
expression is detected in about 6% of cells following treatment with
decitabine and increases to about 10–12% when mice are treated with
the combination of decitabine and belinostat. The apparent clustering
of cells that re-express MLH1 and MAGE-A1 in the xenografts could
represent areas of active proliferation within the tumours, which
would be consistent with decitabine being incorporated into DNA
during S-phase only and cell proliferation being required for
demethylation. For the MAGE-A1 gene promoter decitabine treat-
ment results in a decrease in the methylation of all three CpG sites
studied (Figure 3). However, there is no further reduction in
methylation following addition of belinostat to decitabine, which
suggests that the enhanced gene expression observed with the
combination is not due to direct effects on gene methylation. A study
of the combination of decitabine and trichostatin A on MLH1
expression also concluded that the effect of the HDAC inhibitor was
not due to a further reduction in DNA methylation (Cameron et al,
1999). It is possible that the HDAC inhibitor allows increased access
of the transcription factors to the demethylated gene as a result of
increased levels of histone acetylation and the resulting chromatin
remodelling (Egger et al, 2007).
Re-expression of MLH1 is clearly apparent by 6 days
after treatment and is maximal by about 9 days. As A2780/cp70
is a rapidly growing tumour, we treated with the cytotoxic drug as
early as possible after decitabine treatment (day 6). This is the
schedule used previously for decitabine alone (Plumb et al, 2000).
A2780/cp70 xenografts are resistant to cisplatin. However,
treatment with decitabine sensitises the tumours to cisplatin and
the growth delay is further enhanced by the addition of belinostat
(Figure 4). These results give clear support to the proposal to
use decitabine in combination with a histone deacetylase inhibitor
to enhance the chemo-sensitisation observed with decitabine
alone.
Neither decitabine, belinostat nor the combination had any
effect on tumour growth. This is not surprising as we have not
attempted to use these drugs in the optimal schedule for
antitumour activity. We have already shown that A2780/cp70 is
sensitive to belinostat when mice are treated daily for 7 days
(Plumb et al, 2003). As the aim was to combine the epigenetic
therapies with a cytotoxic drug we have intentionally used low,
non-toxic doses of the agents. Although decitabine treatment
results in a reduced MAGE-A1 methylation in PBMCs the gene is
not re-expressed and this may be due to a lack of the necessary
transcriptional activators (Karpf et al, 2004). Few studies have
examined the effects of demethylating agents on normal cells;
however, there is some evidence that fewer genes become
demethylated than in tumour cells (Liang et al, 2002). This
suggests that epigenetic therapies will not necessarily be associated
with genome-wide effects in normal tissues. Furthermore, the
combination of a low dose of decitabine and the HDAC inhibitor
phenylbutyrate has been shown to inhibit carcinogen-induced lung
tumours in mice (Belinsky et al, 2004). This raises the possibility
that in addition to sensitising drug-resistant tumours to
chemotherapy the epigenetic therapy might also protect the
normal tissues from some of the damage caused by the cytotoxic
agent.
As the dose of decitabine that can be given to patients and hence
the maximum pharmacodynamic effect as a demethylating agent is
limited by toxicity and eventual re-methylation of genes, we
suggest that the combination of decitabine and belinostat could
have a role in increasing the efficacy of chemotherapy in tumours
that have acquired drug resistance due to DNA methylation and
gene silencing.
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